Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Specialty Sites
    • COVID-19
    • Practice Current
    • Practice Buzz
    • Without Borders
    • Equity, Diversity and Inclusion
    • Innovations in Care Delivery
  • Collections
    • Topics A-Z
    • Residents & Fellows
    • Infographics
    • Patient Pages
    • Null Hypothesis
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Specialty Sites
    • COVID-19
    • Practice Current
    • Practice Buzz
    • Without Borders
    • Equity, Diversity and Inclusion
    • Innovations in Care Delivery
  • Collections
    • Topics A-Z
    • Residents & Fellows
    • Infographics
    • Patient Pages
    • Null Hypothesis
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

User menu

  • Subscribe
  • My Alerts
  • Log in

Search

  • Advanced search
Neurology
Home
The most widely read and highly cited peer-reviewed neurology journal
  • Subscribe
  • My Alerts
  • Log in
Site Logo
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

Utility of an immunotherapy trial in evaluating patients with presumed autoimmune epilepsy

  • Michel Toledano, Mayo Clinictoledano.michel@mayo.edu
  • Michel Toledano, Rochester, MN; Jeffrey W. Britton, Rochester, MN; Sean J. Pittock, Rochester, MN.
Submitted June 12, 2014

We thank Dr. Sethi for highlighting these important issues. The majority of patients were tried on IVMP first. IVIg was used as the first agent in pediatric patients or in some patients with GAD65 antibodies. This likely reflects its perceived favorable side effect profile in the case of children, and the concern that those who are GAD65 seropositive may develop frank diabetes if treated with steroids. However, the exact reasoning was not spelled out in the notes reviewed, and the veracity of those concerns is disputable. Of those tried on IVMP first, 56.5% (13/23) responded vs 33% (2/6) of those tried on IVIg (p=0.39). Only half of the patients who failed to respond to the first agent were tried on a second agent but 43% (3/7) of those tried responded. Although this raises the possibility that some patients may respond differentially to these two agents, the study was not adequately powered to answer this question, and currently there is not enough evidence to recommend one over the other.

As to the question of PLEX, our study was not designed to evaluate its utility as part of the evaluation of these patients. Two patients in our cohort received PLEX as rescue therapy during relapses after initial response to IVMP. Although there is reason to believe that the mechanism of action of PLEX is more like IVIg than IVMP, the question as to whether PLEX could be used as a first line agent also remains unanswered.

For disclosures, contact the editorial office at journal@neurology.org.

Navigate back to article

Neurology: 96 (9)

Articles

  • Ahead of Print
  • Current Issue
  • Past Issues
  • Popular Articles
  • Translations

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Activate a Subscription
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology | Print ISSN:0028-3878
Online ISSN:1526-632X

© 2021 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise